任曦医药科技

Renxi Pharmaceutical is an innovative biotechnology company headquartered in Suzhou, China, specializing in the development of targeted protein degradation (TPD) therapies. The company focuses on utilizing molecular glues and PROTAC (Proteolysis-targeting chimera) technologies to target proteins that are traditionally difficult to reach with conventional small molecules. Their research and development efforts are primarily directed toward oncology and neurodegenerative diseases, aiming to provide breakthrough treatments for patients with limited options. Renxi operates out of the BioBAY science park, benefiting from a robust ecosystem for drug discovery and clinical development. The company is currently advancing its internal pipeline through the pre-clinical phase, leveraging structural biology and advanced medicinal chemistry to expand the druggable proteome.